{"id":"lulizumab","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02265744","NCT04066114","NCT03058822","NCT04903054","NCT02843659"],"aliases":["BMS-931699","anti-CD28 domain antibody (anti-CD28 dAb)"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Lulizumab","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Biologic","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Lulizumab","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02265744","phase":"Phase 2","title":"A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatm","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":730,"indication":"Lupus","completionDate":"2017-11-30"},{"nctId":"NCT04066114","phase":"Phase 1","title":"Regulatory T Cell Modulation in Kidney Transplantation With Biologic Blockade of Dual Effector Pathways, CD28 and IL-6 (CTOT-24)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":24,"indication":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","completionDate":"2023-09-14"},{"nctId":"NCT03058822","phase":"Phase 1","title":"A Randomized, Open-label, Parallel-group, Single Subcutaneous Dose, Relative Bioavailability Study of the Pharmacokinetics of Lulizumab (BMS-931699) From Prefilled Syringe (Process A) Compared to Drug","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":5,"indication":"Healthy","completionDate":"2017-03-30"},{"nctId":"NCT04903054","phase":"Phase 2","title":"Selective CD28 Blockade With Lulizumab Compared to CNI Inhibition With Tacrolimus in Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":0,"indication":"Kidney Transplantation, Renal Transplant Recipients","completionDate":"2022-09-22"},{"nctId":"NCT02843659","phase":"Phase 2","title":"A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjö","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":45,"indication":"Sjögren's Syndrome","completionDate":"2017-07-24"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Biologic","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}